Goldstein Frederick J
Department of Biomedical Sciences, Philadelphia College of Osteopathic Medicine, PA 19131-1610, USA.
J Am Osteopath Assoc. 2002 Sep;102(9 Suppl 3):S15-21.
Administration of opioids to alleviate moderate to severe acute pain and chronic cancer pain is an established management process. However, advancements in clinical pharmacologic research have shown that opioids are also effective in chronic noncancerous pain. Many patients properly treated for prolonged periods with opioids develop tolerance and subsequently, physical dependence. This process is not necessarily harmful to the patient and will not cause the patient to develop an addiction (properly defined as psychologic dependence). For many patients who have been on opioid therapy for months or years, analgesic effectiveness tragically becomes less. In addition, opioid-induced constipation can be severe and cause pain; patients do not develop tolerance to this adverse reaction. Therefore, such issues become a management problem and require additional intervention. Currently, many different classes of drugs can serve as effective adjuncts to opioids for treatment of pain. Adding adjunctive medication to opioid therapy improves pain management primarily by nonopioid mechanisms of action. Clinical outcomes of such combinations include greater analgesia and attenuation of opioid-induced adverse reactions such as nausea and vomiting, constipation, sedation, and respiratory depression. Adjuncts include acetaminophen, antiarrhythmics, anticonvulsants, antidepressants, antipsychotics, baclofen, benzodiazepines, capsaicin, calcium channel blockers, clonidine hydrochloride, central nervous system stimulants, corticosteroids, local anesthetics, N-methyl-D-aspartate receptor antagonists, nonsteroidal antiinflammatory drugs, pentoxifylline, and scopolamine. Some adjuncts (eg, acetaminophen) are routinely used today, whereas others (eg, nifedipine [calcium channel blocker]) are used on a limited basis but have great potential for more widespread application. All professionals (eg, nurses, pharmacists, physicians, physicians' assistants, social workers, members of the clergy) involved in treating patients with unresolved pain recognize this to be an extraordinary and delicate time. It is when patients are likely to request physicians to provide some method to accelerate their death. Thus, inadequate analgesia can become a suicidogen, ie, any factor that causes a patient to want to commit suicide. Incorporation of adjuncts to opioid therapy can serve to lessen pain and improve quality of life for a suffering patient.
使用阿片类药物缓解中度至重度急性疼痛和慢性癌痛是既定的治疗方法。然而,临床药理学研究的进展表明,阿片类药物对慢性非癌性疼痛也有效。许多长期接受阿片类药物适当治疗的患者会产生耐受性,随后出现身体依赖。这个过程不一定对患者有害,也不会导致患者成瘾(成瘾的正确定义是心理依赖)。对于许多接受阿片类药物治疗数月或数年的患者来说,镇痛效果不幸地变差了。此外,阿片类药物引起的便秘可能很严重并导致疼痛;患者不会对这种不良反应产生耐受性。因此,这些问题成为一个管理难题,需要额外的干预措施。目前,许多不同类别的药物可作为阿片类药物治疗疼痛的有效辅助药物。在阿片类药物治疗中添加辅助药物主要通过非阿片类作用机制改善疼痛管理。此类联合用药的临床结果包括更强的镇痛效果以及减轻阿片类药物引起的不良反应,如恶心、呕吐、便秘、镇静和呼吸抑制。辅助药物包括对乙酰氨基酚、抗心律失常药、抗惊厥药、抗抑郁药、抗精神病药、巴氯芬、苯二氮䓬类、辣椒素、钙通道阻滞剂、盐酸可乐定、中枢神经系统兴奋剂、皮质类固醇、局部麻醉药、N-甲基-D-天冬氨酸受体拮抗剂、非甾体抗炎药、己酮可可碱和东莨菪碱。一些辅助药物(如对乙酰氨基酚)如今经常使用,而其他一些药物(如硝苯地平[钙通道阻滞剂])使用有限,但有更广泛应用的巨大潜力。所有参与治疗疼痛未得到缓解患者的专业人员(如护士、药剂师、医生、医师助理、社会工作者、神职人员)都认识到这是一个特殊而微妙的时期。正是在这个时候,患者可能会要求医生提供某种加速其死亡的方法。因此,镇痛不足可能成为一种自杀诱发因素,即任何导致患者想要自杀的因素。在阿片类药物治疗中加入辅助药物有助于减轻疼痛,提高痛苦患者的生活质量。